These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17878922)

  • 1. Mouse models and the RANKL/OPG axis in myeloma bone disease.
    Dingli D; Russell SJ
    Leukemia; 2007 Oct; 21(10):2090-3. PubMed ID: 17878922
    [No Abstract]   [Full Text] [Related]  

  • 2. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
    Pivonka P; Zimak J; Smith DW; Gardiner BS; Dunstan CR; Sims NA; Martin TJ; Mundy GR
    J Theor Biol; 2010 Jan; 262(2):306-16. PubMed ID: 19782692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of the osteoclast in pathogenesis of multiple myeloma].
    Zhang JH; Fu JX; Zhang XH; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
    Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
    Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sex hormones on bone metabolism of the otic capsule--an overview.
    Horner KC
    Hear Res; 2009 Jun; 252(1-2):56-60. PubMed ID: 19121641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct effects of osteoprotegerin on human bone cell metabolism.
    Grundt A; Grafe IA; Liegibel U; Sommer U; Nawroth P; Kasperk C
    Biochem Biophys Res Commun; 2009 Nov; 389(3):550-5. PubMed ID: 19748486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.
    Baud'huin M; Lamoureux F; Duplomb L; Rédini F; Heymann D
    Cell Mol Life Sci; 2007 Sep; 64(18):2334-50. PubMed ID: 17530461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rank/Rankl/opg: literature review.
    Silva I; Branco JC
    Acta Reumatol Port; 2011; 36(3):209-18. PubMed ID: 22113597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
    Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S
    Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.